PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Levosulpiride→

Levosulpiride PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
23672-07-3
Molecular formula
C15H23N3O4S
Molecular weight
341.43 g/mol
Drug class
Substituted benzamidedopamine D2/D3 receptor antagonist with prokinetic and antipsychotic activity
Mechanism of action
Blocks dopamine D2-family receptors centrally and in the enteric nervous system. Peripheral D2 blockade in the myenteric and submucosal plexuses enhances cholinergic activity and gastrointestinal motility; central dopaminergic blockade contributes to its antipsychotic and antiemetic pharmacology.
Indications / reported uses
  • Symptomatic treatment of functional dyspepsia and selected upper gastrointestinal motility disorders where authorised.
  • Psychiatric use for selected psychotic disorders is product- and jurisdiction-specific.

Sources: https://www.torrentpharma.com/assets/1398_fb0cb18995.pdf · https://pmc.ncbi.nlm.nih.gov/articles/PMC10036984/ · https://pubmed.ncbi.nlm.nih.gov/?term=levosulpiride+prokinetic+mechanism · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Levosulpiride PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Levosulpiride Permitted Daily Exposure (PDE) report (the Levosulpiride PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Levosulpiride Occupational Exposure Limit (OEL) report (the Levosulpiride OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.